STING agonists are also currently being examined in preclinical breast cancer models in combination with ubiquitinated protein nanovaccines (265), anti-CD47 monoclonal antibodies (266), and CAR-T cell therapy (267). The gene discussed is STING1; the disease is breast cancer.